Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
death D28 | 0.88 [0.82, 0.94] | | < 1 | | 27% | 61 studies (61/-) | 100.0 % | some concern | critical | moderate | crucial | - |
death or transfer to ICU | 0.79 [0.50, 1.24] | | < 1 | | 0% | 2 studies (2/-) | 84.9 % | some concern | not evaluable | moderate | crucial | - |
deaths | 0.89 [0.85, 0.93] | | < 1 | | 22% | 102 studies (102/-) | 100.0 % | some concern | critical | moderate | crucial | 1 |
deaths (time to event analysis only) | 0.81 [0.69, 0.94] | | < 1 | | 31% | 15 studies (15/-) | 99.7 % | some concern | low | moderate | crucial | - |
clinical deterioration | 0.71 [0.58, 0.86] | | < 1 | | 49% | 21 studies (21/-) | 100.0 % | some concern | low | moderate | important | - |
clinical improvement | 1.15 [1.06, 1.26] | | > 1 | | 39% | 29 studies (29/-) | 100.0 % | some concern | critical | moderate | important | - |
clinical improvement (14-day) | 1.31 [1.06, 1.62] | | > 1 | | 42% | 9 studies (9/-) | 99.3 % | some concern | serious | moderate | important | - |
clinical improvement (28-day) | 1.53 [1.09, 2.14] | | > 1 | | 49% | 10 studies (10/-) | 99.3 % | some concern | critical | moderate | important | - |
clinical improvement (7-day) | 1.29 [0.82, 2.01] | | > 1 | | 61% | 5 studies (5/-) | 86.6 % | some concern | not evaluable | moderate | important | - |
clinical improvement (time to event analysis only) | 1.11 [1.01, 1.22] | | > 1 | | 20% | 13 studies (13/-) | 98.9 % | some concern | critical | moderate | important | - |
death or ventilation | 0.90 [0.85, 0.96] | | < 1 | | 57% | 24 studies (24/-) | 100.0 % | some concern | critical | moderate | important | - |
hospital discharge | 1.07 [1.00, 1.15] | | > 1 | | 63% | 12 studies (12/-) | 97.1 % | some concern | critical | moderate | important | - |
hospitalization | 1.00 [0.14, 7.34] | | < 1 | | 0% | 1 study (1/-) | 50.0 % | some concern | not evaluable | moderate | important | - |
mechanical ventilation | 0.90 [0.82, 0.98] | | < 1 | | 15% | 28 studies (28/-) | 99.4 % | some concern | critical | moderate | important | 1 |
radiologic improvement (14-day) | 3.02 [1.77, 5.14] | | > 1 | | 0% | 3 studies (3/-) | 100.0 % | some concern | not evaluable | moderate | important | - |
viral clearance | |